
The development of an effective new Alzheimer‘s medication could mark “the beginning of the end” for the neurological condition.
At a symposium in Amsterdam today, US pharmaceutical behemoth Eli Lilly will present the complete clinical trial findings for its Alzheimer’s medicine donanemab.